Developed by Medytox’s proprietary SHAPE™ (Stabilized Hyaluronic Acid Precision Engineering) process, this medical-grade filler undergoes dual-phase cross-linking for optimized chain alignment. The 20mg/mL non-animal HA matrix demonstrates 78% higher resistance to hyaluronidase degradation compared to conventional fillers (in vitro testing). Particle size distribution of 250-500μm ensures natural integration while maintaining 92% structural integrity at 12 months post-implantation.
Product Specifications